Tempus AI, Inc. (NASDAQ:TEM) experienced a notable increase in its stock price on Monday, following the release of preliminary fourth-quarter and full-year results for 2025. The company reported an anticipated revenue of approximately $1.27 billion, representing an 83% growth year-over-year. This figure includes about 30% organic growth when excluding contributions from Ambry. For the fourth quarter alone, Tempus AI forecasts revenue of around $367 million, which also signifies an 83% increase compared to the same period last year.
In addition to its financial performance, Tempus AI announced the signing of two significant contracts aimed at enhancing cancer testing and patient care. The first partnership is a multi-year collaboration with NYU Langone Health, focused on advancing cancer treatment through molecular profiling and data analytics. Dr. Ezra Cohen, Chief Medical Officer for Oncology at Tempus, emphasized the company’s commitment to generating actionable insights that will refine existing assays and foster the development of innovative diagnostic tools, ultimately enabling personalized patient care.
The second agreement with Northwestern Medicine aims to expand access to genomic testing for cancer patients, ensuring availability for nearly all cancer types, including early-stage diagnoses. This initiative will provide clinicians with deeper insights into individual patient cases, supporting the creation of tailored and effective treatment plans.
As of Monday, Tempus AI shares had risen 3.86%, reaching $68.83.
Why this story matters
Key takeaway
Opposing viewpoint
